๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Metastatic Colorectal Cancer (CRC)
Clinical trial register · China

Metastatic Colorectal Cancer (CRC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 4 Guangzhou 4 Nanjing 2 Shanghai 2 Shijiazhuang 2
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing4 Guangzhou4 Nanjing2 Shanghai2 Shijiazhuang2
All 21 locations
Target enrolment
to

Metastatic Colorectal Cancer (CRC) trials in China

17 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer
NCT07790510Metastatic Colorectal Cancer (CRC)
Haisco Pharmaceutical Group Co., Ltd.
Phase 1/2
180
Beijing
2026-08-12
Not yet open
A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance
NCT07622550Metastatic Colorectal Cancer (CRC)
Jiangsu Cancer Institute & Hospital
Phase 2
80
Changzhou, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Wuxi, Xuzhou
2026-06-15
Not yet open
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
NCT07621497Metastatic Colorectal Cancer (CRC)
Sun Yat-sen University
Phase 2
229
Guangzhou
2026-06-01
Not yet open
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
NCT07585279Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
Hebei Medical University Fourth Hospital
Phase 2/3
408
Shijiazhuang
2026-05-20
Recruiting
Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC
NCT07724223Metastatic Colorectal Cancer (CRC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
46
Beijing
2026-01-16
Not yet open
Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer
NCT07286695Metastatic Colorectal Cancer (CRC), Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
292
Beijing
2025-12-31
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
Summit Therapeutics
Phase 3
600
Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Haikou, Shijiazhuang, Harbin
2025-11-18
Not yet open
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
NCT07233850Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2
300
Wuhan
2025-11
Recruiting
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
NCT07309289Metastatic Colorectal Cancer (CRC)
Shanghai Zhongshan Hospital
Phase 3
144
Shanghai
2025-07-01
Not yet open
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
NCT07009145Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer
Qianfoshan Hospital
Phase 2
22
Jinan
2025-06-27
Recruiting
Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)
NCT06958419Immune Checkpoint Therapy, Radiotherapy, Metastatic Colorectal Cancer (CRC)
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2/3
286
Guangzhou
2025-05-01
Recruiting
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
NCT06856187Metastatic Colorectal Cancer (CRC)
Fudan University
Phase 2
119
Shanghai
2025-02-28
Recruiting
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
NCT06825624Metastatic Colorectal Cancer (CRC)
Hansoh BioMedical R&D Company
Phase 1
560
Hangzhou
2024-10-03
Recruiting
Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer
NCT07504523Metastatic Colorectal Cancer (CRC)
Ying Yuan, MD
Phase 1
20
Hangzhou
2023-11-01
By invitation
Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer
NCT06849362Metastatic Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer, Immunotherapy
Yue Gou
Observational
200
Changsha
2019-12-01
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/metastatic-colorectal-cancer-crc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies listing the condition Metastatic Colorectal Cancer (CRC).

How many Metastatic Colorectal Cancer (CRC) trials are recruiting in China?

8 of the 17 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 0 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Metastatic Colorectal Cancer (CRC)), 17 studies
PhaseStudiesRecruitingShare
Phase 28247.1%
Phase 2/33117.6%
Phase 12211.8%
Phase 32211.8%
Observational105.9%
Phase 1/2115.9%

Most active sponsors

Lead sponsors with the most studies (Metastatic Colorectal Cancer (CRC))
Lead sponsorStudiesRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences21
Jiangsu Cancer Institute & Hospital20
Sun Yat-sen University20
Fudan University11
Haisco Pharmaceutical Group Co., Ltd.11
Hansoh BioMedical R&D Company11
Hebei Medical University Fourth Hospital10
Qianfoshan Hospital10
Shanghai Zhongshan Hospital11
Shenyang Sunshine Pharmaceutical Co., LTD.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.